Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a community program cut the time to treat psychosis?

NCT ID NCT05813457

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called PRESTO that aims to identify and treat first-episode psychosis sooner. The program educates the public, trains frontline workers like doctors and teachers, and provides a mobile team to connect patients to care. Researchers will measure whether this reduces the time a person goes untreated, which may improve their long-term outlook. The trial involves 416 participants across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PRESTO Early Identification Program (community education, training for frontline workers, and a mobile care team)
What this could lead to
If successful, this program could become a model for reducing delays in treating first-episode psychosis, potentially improving long-term outcomes for patients.
What could go wrong
This is a behavioral intervention study, not a drug trial. Results depend on community uptake and may not be easily replicated in other regions. The study is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 416 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder established according to DMS 5 * Never having taken neuroleptic treatment for antipsychotic purposes, except for the current episode and for a duration of \< 6 month * Oral consent of the patient or, for minors, of his/her parents to participate in the study Exclusion Criteria: * Patients already treated and followed for FPE * Brief psychotic state not requiring specific management

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychotic episode are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychiatric disorder psychotic disorder schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychotic episode

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Montpellier

    RECRUITING

    Montpellier, 34090, France

  • CHU de Nîmes

    RECRUITING

    Nîmes, 30900, France

  • Chu Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, 63003, France

  • Chu Grenoble

    RECRUITING

    Grenoble, 38000, France

  • Chu Saint Etienne

    RECRUITING

    Saint-Etienne, 42100, France

  • Hospices Civils de Lyon

    RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.